Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia

Sorich MJ, Horowitz JD, Sorich W, Wiese MD, Pekarsky B, Karnon JD

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
24279856

DOI
10.2217/pgs.13.164

Indexing Status
Subject indexing assigned by NLM

MeSH
Acute Coronary Syndrome /drug therapy /genetics /pathology; Adenosine /analogs & derivatives /therapeutic use; Alleles; Aryl Hydrocarbon Hydroxylases /genetics; Australia; Cost-Benefit Analysis /economics; Cytochrome P-450 CYP2C19; Genotype; Humans; Markov Chains; Ticlopidine /analogs & derivatives /therapeutic use

AccessionNumber
22013052174

Date bibliographic record published
24/12/2013